Knockdown of Virus Antigen Expression Increases Therapeutic Vaccine Efficacy in High-titer HBV Carrier Mice.
Name:
Michler et al.pdf
Size:
15.55Mb
Format:
PDF
Description:
original manuscript plus suppl ...
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Authors
Michler, ThomasKosinska, Anna D
Festag, Julia
Bunse, Till
Su, Jinpeng
Ringelhan, Marc
Imhof, Hortenzia
Grimm, Dirk
Steiger, Katja
Mogler, Carolin
Heikenwalder, Mathias
Michel, Marie-Louise
Guzman, Carlos A
Milstein, Stuart
Sepp-Lorenzino, Laura
Knolle, Percy
Protzer, Ulrike
Issue Date
2020-01-28
Metadata
Show full item recordAbstract
In both models of HBV infection, mice that express hepatocyte-specific small hairpin RNAs or that were given subcutaneous injections of siRNAs had reduced levels of HBV antigens, HBV replication, and viremia (1-3 log10 reduction), compared to mice given control RNAs. Vaccination induced production of HBV-neutralizing antibodies, and increased numbers and functionality of HBV-specific, CD8+ T-cells in mice with low, but not in mice with high levels of HBV antigen. Mice with initially high titers of HBV and knockdown of HBV antigen expression, but not mice with reduced viremia following administration of entecavir, developed polyfunctional, HBV-specific CD8+ T cells and HBV was eliminated.Citation
Gastroenterology. 2020 Jan 28. pii: S0016-5085(20)30125-6. doi: 10.1053/j.gastro.2020.01.032.Affiliation
HZI,Helmholtz-Zentrum für Infektionsforschung GmbH, Inhoffenstr. 7,38124 Braunschweig, Germany.Publisher
ElsevierJournal
GastroenterologyPubMed ID
32001321Type
ArticleLanguage
enISSN
1528-0012ae974a485f413a2113503eed53cd6c53
10.1053/j.gastro.2020.01.032
Scopus Count
The following license files are associated with this item:
- Creative Commons
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-ShareAlike 4.0 International
Related articles
- A Highly Attenuated Vesicular Stomatitis Virus-Based Vaccine Platform Controls Hepatitis B Virus Replication in Mouse Models of Hepatitis B.
- Authors: Moshkani S, Chiale C, Lang SM, Rose JK, Robek MD
- Issue date: 2019 Mar 1
- Virus-Like Vesicle-Based Therapeutic Vaccine Vectors for Chronic Hepatitis B Virus Infection.
- Authors: Reynolds TD, Buonocore L, Rose NF, Rose JK, Robek MD
- Issue date: 2015 Oct
- IL-12-based vaccination therapy reverses liver-induced systemic tolerance in a mouse model of hepatitis B virus carrier.
- Authors: Zeng Z, Kong X, Li F, Wei H, Sun R, Tian Z
- Issue date: 2013 Oct 15
- Activation of CD4 T cells during prime immunization determines the success of a therapeutic hepatitis B vaccine in HBV-carrier mouse models.
- Authors: Su J, Brunner L, Ates Oz E, Sacherl J, Frank G, Kerth HA, Thiele F, Wiegand M, Mogler C, Aguilar JC, Knolle PA, Collin N, Kosinska AD, Protzer U
- Issue date: 2023 Apr
- Vaccination with a fusion DNA vaccine encoding hepatitis B surface antigen fused to the extracellular domain of CTLA4 enhances HBV-specific immune responses in mice: implication of its potential use as a therapeutic vaccine.
- Authors: Zhou C, Peng G, Jin X, Tang J, Chen Z
- Issue date: 2010 Nov